Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
The video is divided into chapters to help you navigate through the content using the seek bar
Hear from our expert speakers: Professor Alastair Greystoke, Honorary Medical Oncologist at Newcastle upon Tyne Hospitals; Professor Neal Navani, Consultant Respiratory Physician at University College London Hospital; and Dr Tom Newsom-Davis, Consultant Medical Oncologist at Chelsea and Westminster Hospital.
An expert-led webinar series
The LCEF webinar series aims to share knowledge, experience, and resources to support improvements in service delivery, capacity pressures, and lung pathway efficiency to maximise the quality of lung cancer care in the UK. This programme has been designed by our expert Steering Committee to ensure its relevance to your clinical practice.
Roche have fully funded and organised the LCEF series and the agenda has been created in collaboration with the steering committee and faculty whom were paid by Roche UK.
Want to know more about how the LCEF 2025 content could be relevant to you and your trust?
Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.
Tecentriq as monotherapy is indicated for the 1L treatment of adult patients with advanced NSCLC who are
ineligible for platinum-based therapy (platinum ineligible criteria can be found in section 5.1 of the SPC)
Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
ALECENSA as monotherapy is indicated as adjuvant treatment for adult patients with Stage IB to IIIA* ALK+ NSCLC following complete tumour resection. ALECENSA as monotherapy is indicated for the first-line treatment of adult patients with ALK+ advanced NSCLC.1
Abbreviations:
CNE, clinical nurse educator; DLP, disease level partner; IV, intravenous; LCEF, Lung Cancer Expert Forum; SACT, systemic anti-cancer therapy; SC, subcutaneous